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Background: Endocrine therapy (ET) plus cyclin-dependent-kinases 4/6 inhibitors (CDK4/6i) represents
the standard treatment for luminal-metastatic breast cancer (MBC). However, prospective head-to-head
comparisons are still lacking for 1st line (L) options, and it is still crucial to define the best strategy
between 1st and 2nd L.
Materials and methods: 717 consecutive luminal-MBC pts treated between 2008 and 2020 were analyzed
at the Oncology Department of Aviano and Udine, Italy. Differences about survival outcomes (OS, PFS and
PPS) were tested by log-rank test. The attrition rate (AR) between 1st and 2ndL was calculated.
Results: At 1stL, pts were treated with ET (49%), chemotherapy (CT) (31%) and ET-CDKi (20%) while, at
2ndL, 33% received ET, 33% CT and 8% ET-CDKi. Overall AR was 10%, 7% for CT, 8% for ET and 17% for ET-
CDKi. By multivariate analysis, 1stL ET-CDK4/6i showed a better mPFS1 and OS. Moreover, 2ndL ET-CDK4/
6i demonstrated better mPFS2 compared to ET and CT. Notably, 1stL ET-CDKi resulted in higher mPFS than
2ndL ET-CDKi. Intriguingly, 1stL ET-CDK4/6i was associated with worse mPPS compared to CT and ET.
Secondarily, 1stL ET-CDK4/6i followed by CT had worse OS compared to 1stL ET-CDK4/6i followed by ET.
Notably, none of baseline characteristics at 2ndL influenced 2ndL treatment choice (ET vs. CT) after ET-
CDKi.
Conclusion: Our real-world data demonstrated that ET-CDKi represents the best option for 1stL luminal-
MBC compared to ET and CT. Also, the present study pointed out that 2ndL ET, potentially combined with
other molecules, could be a feasible option after CDK4/6i failure, postponing CT on later lines.
© 2021 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Over the last decade, thanks to a combination of newUniversity of Udine, 33100,
Medical Oncology and Cancer
no (CRO), IRCCS, 33081, Avi-
Basile).
ier Ltd. This is an open access artictherapeutic agents and diagnostic strategies, the outcome and
management of patients with metastatic breast cancer (mBC)
gradually improved both on a survival and quality of life stand
point. The combination CDK4/6 inhibitors (CDK4/6i) (i.e Palbociclib,
Ribociclib and Abemaciclib) with endocrine therapy (ET, i.e. aro-
matase inhibitors (AI) or Fulvestrant) has significantly increased
objective response rate (ORR) and progression-free survival (PFS) of
first- and second-line treatments in patients with hormone re-
ceptor positive, HER2 negative (luminal) mBC. Although no head-le under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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tematic reviews and meta-analyses have further supported the
efficacy of the combinations in terms of PFS and of overall survival
(OS) [1 e 8].
The growing number of potentially active agents in different
treatment lines is increasing the complexity of drug development
making the choice of study endpoints even more critical [9].
Indeed, overall survival (OS) has been considered the most relevant
outcome measure in mBC trials, being an objective measure of the
clinical benefit. However, survival may be influenced by post-
protocol treatments and some randomised trials might be under-
powered to detect OS differences notwithstanding a benefit in PFS
[10,11]. To overcome these limits, recent trials have been designed
to detect a clinical benefit in terms of PFS and time-to-treatment
progression (TTP), as competing causes of death and further-line
treatments may have less impact [11].
A critical, still unmet, need is to improve resistance character-
ization to ET and CDK4/6i, such as ESR1 genetic and epigenetic al-
terations, FGFR1 amplification RB1 loss or CCNE1 amplification to
anticipate clinical progression and guide subsequent treatment
lines [12e16]. As a matter of fact, ET and CDK4/6i resistance might
confer to MBC aggressive features such as epithelial to mesen-
chymal transition that eventually are clinically translated in rapid
progression and ultimately in an unfavourable prognosis [15,17].
Furthermore, there is no evidence supporting post CDK4/6i pro-
gression decision-making, and different strategies such as CDK4/6i
beyond progression, CDK4/6i or ET switch and the addition of other
targeted agents, including PI3K inhibitors are being studied.
The aim of this study was to provide real-world treatment
patterns data for luminal MBC, and to give hypothesis generation
insights of their consequent impact on clinical outcome measures.
2. Materials and methods
2.1. Study design
This was an observational, multicentricer, retrospective study,
that evaluated a consecutive series of 717 patients with luminal
mBC. The study was conducted in accordance with the ethical
principles deriving from the Helsinki Declaration and the current
legislation on Observational Studies (Circular Min. Sal. Of
September 6, 2002). The study was approved by the Departmental
Review Board and by the Ethics Committee (Protocol number CRO-
2019-85).
Data concerning clinico-pathological characteristics, treatments
for metastatic disease, and blood tests performed within 30 days of
the first- and second-line treatment start, were collected retro-
spectively. Primary objective of this study was to evaluate the
impact first- and second-line of treatment strategies in terms of
PFS, post-progression survival [PPS] after first-line, and OS) ac-
cording to treatment type (chemotherapy, CT; ET alone; ET com-
bined with CDK4/6i). Secondary objectives were to evaluate
attrition rate according to first-line treatment, the probability of
receiving chemotherapy after CDK4/6i, and factors determining the
choice of second-line treatment after CDK4/6i.
PFS was defined as time from first-line therapy start until pro-
gression disease or death from any cause. According to the treat-
ment line, PFSwas defined as PFS1 and PFS2. PPSwas defined as the
interval between progression and death or last follow-up.
OS was defined as the time between first-line therapy start and
death from any cause.
The attrition rate related to first-line treatment was defined as
the proportion of patients who started therapy but who, at the time
of disease progression were unable to receive further treatment
due to disease progression, death, toxicity, or other clinical105conditions.
2.2. Study population
All patients had histologically or cytologically confirmed
luminal (HR positive/HER2 negative) mBC. They provided informed
consent for the use of clinical data that were rendered anonymous
for purposes of clinical research, epidemiology, training and disease
study.
The study population included consecutive patients treated at
the Department of Medical Oncology, National Cancer Institute of
Aviano and at the Oncology Department of Udine, Italy, from
January 2008 to Janury 2020. Data have been obtained from elec-
tronic and paper-chart review according to strict privacy standards.
2.3. Statistical analysis
Patients’ clinico-pathological characteristics were summarized
through descriptive analysis. Categorical variables were reported as
frequency distributionwhereas continuous variables were reported
as median value and range. Differences in terms of survival out-
comes were tested by log-rank test and represented by Kaplan-
Meier survival curves. Analyses were stratified by line of treat-
ment and type of treatment received.
A Cox proportional-hazards regression model, including also
potential confounders (e.g. age, ET naïve, ECOG PS) was used to
calculate hazard ratios (HR) of death, with the corresponding 95%
confidence intervals (CI), in the different subgroups of patients
identified according treatment. To better evaluate if baseline fea-
tures at second-line could influence the choice of CT or ET after fist-
line CDK4/6i, a logistic analysis was performed.
A two-sided P < 0.05 was considered statistically significant.
Statistical analyses will be performed with STATA (StataCorp.
(2015) Stata Statistical Software: Release 14.2. College Station, TX:
StataCorp LP).
2.4. Sample size calculation
The sample size was estimated in order to obtain a good per-
formance of the statistical model for the association between pa-
tient and tumor characteristics with outcome measures in the
multivariate analysis. The aim of the sampling was the achievement
of a good “goodness of fit” from the regression model according to
Peduzzi and Concato [18,19]. Therefore, considering 20e50 events
per variable (EPV) and a final model with approximately 6e7 var-
iables, more than 350 EPV are necessary to obtain an accurate
estimation of the statistical model. In the present study, we
observed 575 events for PFS1, 466 for PFS2, and 443 for OS.




The study included 717 womenwith a diagnosis of luminal mBC
who underwent first-line treatment (clinical, pathologic and
treatment characteristics are displayed in Table 1). Overall, 29% of
patients had a de novo mBC, 78% were post-menopausal and 15%
had ECOG PS > 1. Moreover, 49%, 30% and 20% had respectively
visceral, bone-only and non-visceral disease, while, 26% of cases
had 3 metastatic sites and 66% had 5 metastatic lesions. Tumor
burden was, moreover, classified in 3 groups by combining meta-
static sites and number of lesions. In particular, group 1 (25%) had
<3 metastatic sites and 5 lesions, group 2 (45%) <3 metastatic
Table 1
Patient’s characteristics










Ki-67 on primary tumor
<14 % 181 25.24%
14 % 430 59.97%
Missing 106 14.78%
ER
10 % 25 3.49%
>10 % 594 82.85%
Missing 98 13.67%
BMI (kg/m2)
< 25 263 36.68%
 25 293 40.86%
Missing 161 22.45%




















Sites - first line
Bone only 218 30.40%
No visceral 141 19.67%
Visceral 353 49.23%
Missing 5 0.70%









<3 sites and 5 lesions 177 24.69%
3 sites and 5 lesions/ < 3 sites and > 5 lesions 321 44.77%
 3 sites and >5 lesions 166 23.15%
Missing 54 7.53%
ECOG PS e first line
 1 494 68.90%









ET plus mTORi after ET or CT (17 pts)
ET plus mTORi after ET plus CDK4/6i (4 pts)
ET plus CDK 4/6i 61 8.51%
None 51 7.11%
Table 1 (continued )
Variables N (tot 717) Frequencies
Missing 130 18.13%
Sites - second line
Bone only 117 16.32%
No visceral 103 14.37%
Visceral 314 43.79%
None therapy 51 7.11%
Missing 132 18.41%
Number of lesions e second line
<3 sites 343 47.84%
3 199 27.75%
no therapy 51 7.11%
Missing 124 17.29%
Number of lesions - second line
5 lesions 70 9.76%
<5 lesions 449 62.62%
No therapy 51 7.11%
Missing 147 20.50%
Metastatic sites score- second line
<3 sites and 5 lesions 65 9.07%
3 sites and 5 lesions/ < 3 sites and > 5 lesions 260 36.26%
 3 sites and >5 lesions 194 27.06%
No therapy 51 7.11%
Missing 147 20.50%
Change sites between first and second line
No visceral / no visceral 106 14.78%
Visceral / visceral 366 51.05%
No visceral / visceral 62 8.65%
No therapy 51 7.11%
Missing 132 18.41%
ECOG PS- second line
1 327 45.61%
>1 97 13.53%
No therapy 51 7.11%
Missing 242 33.75%
Treatment strategies
ET plus CDK 4/6 / ET 19 2.65%





ET followed by ET plus CDK 4/6 40 5.58%
ET followed by ET or CT 254 35.43%
CT followed by ET or CT 194 27.06%
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106sites and >5 lesions or 3 metastatic sites and 5lesions, group 3
(23%) had 3 metastatic sites and >5 lesions.
Overall, 31% received first-line CT, 49% ET alone and 20%
received ET plus CDK4/6i. In second-line, 33% of patients received
CT, 33% ET alone and 8% ET plus CDK4/6i. In terms of treatment
strategy, 27% of patients received CT followed by ET or CT, 35%
received ET followed by CTor ET, 3% ET plus CDK4/6i followed by CT,
3% ET plus CDK4/6i followed by ET and 6% received ET followed by
ET plus CDK4/6i (Table S1eS2).
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tile: 32.65e102.94 months), median PFS1 was 14.96 months (25th-
75th percentile: 6.77e28.27), median PFS2 was 7.07 months (25th-
75th percentile: 3.39e13.71) median PPS1 was 28.44 months
(25th-75th percentile: 11.97e46.92), and median OS was 47.15
months (25th-75th percentile: 22.88e77.52).3.2. Treatment strategies and tumor burden have a significant
impact on survival outcomes
3.2.1. PFS1
Univariate analysis for PFS1 showed that visceral disease, having
3 and >5 metastatic sites, ECOG PS > 1, Ki67  14% and being
previously exposed to ET were significantly associated with worse
survival (Figure S1A-B-C). Conversely, de novo metastatic disease
was associated with better PFS1. Patients treated with first-line ET
(HR 1.77, p< 0.001, 95% C.I. 1.33e2.36) or CT (HR 1.92, p< 0.001, 95%
C$I 1.42e2.59) experienced worse prognosis than patients treated
with ET plus CDK4/6i. All variables retained their significance after
multivariate analysis, in particular type of treatment received (HR
1.94, p < 0.001, 95%C.I. 1.37e2.73 for ET, HR 1.93, p < 0.001, 95%C.I.
1.36e2.75 for CT) (Table 2, Fig. 1).3.2.2. PFS2
Visceral involvement (HR 1.36, p0.005, 95%C.I. 1.10e1.68), ECOG
PS > 1 at second-line (HR 1.81, p < 0.001, 95%C.I. 1.42e2.31), having
3sites and >5 lesions (HR 1.69, p ¼ 0.001, 95%C.I. 1.24e2.30), Ki-Table 2


















Not visceral 1.17 0.188
Visceral 1.29 0.009
Metastatic sites score
<3 sites and 5 lesions 1.00
3 sites and 5 lesions/ < 3 sites and > 5 lesions 1.09 0.442






>10 % 1.18 0.499
Ki-67 on primary tumor:
<14 % 1.00





ET plus CDK 4/6 inhibitors 1.00
ET 1.77 <0.001
CT 1.92 <0.001
1076714% (HR1.41, p¼ 0.002, 95%C.I. 1.13e1.76) and treatments other
than ET plus CDK4/6i (ET: HR1.65, p ¼ 0.004, 95%C.I. 1.17e2.32; CT:
HR 1.75, p ¼ 0.001, 95%C.I. 1.24e2.47) were linked with worse
prognosis after univariate analysis in terms of PFS2. After multi-
variate analysis, second-line treatment retained its significance,
showing that ET or CT compared with ET/CDK4/6i combination
were burdened byworse prognosis (respectively HR 1.67, p¼ 0.009,
95%C.I. 1.13e2.44 and HR 1.79, p ¼ 0.003, 95% C.I. 1.22e2.61)
(Table S3, Figure S2).
Median PFS1 for patients receiving first-line CDK4/6i was 22.26
months (25th-75th percentile: 8.28 e not reached). Conversely,
median PFS2 for patients receiving second-line CDK4/6i was 12.26
months (25th-75th percentile: 5.16e22.32 months) (Figure S3).3.2.3. PPS
Univariate analysis for PPS1, showed a trend for better PPS in
women treated with first-line ET as compared to ET plus CDK4/6i
(HR: 0.63, C$I.: 0.37e1.06, p ¼ 0.08) (Figure S4).3.2.4. OS
A trend towards better prognosis in terms of OS was observed in
patients treated with first-line CDK4/6i (Table 3, Fig. 2A). In uni-
variate analysis, ET followed by ET plus CDK4/6i, ET plus CDK4/6i
followed by ET, ET followed by ET or CT and CT followed by CT or ET
showed a better survival compared with ET plus CDK4/6i followed
by CT. Results were confirmed in multivariate analysis (Table 3,
Fig. 2B).Multivariate analysis




1.02 e 1.43 1.45 0.001 1.17-1.79
0.69 e 0.99
0.93 e 1.48 1.26 0.132 0.93-1.71
1.07 e 1.56 1.03 0.812 0.78-1.37
0.88 e 1.34 1.25 0.087 0.97-1.60
1.16 e 1.87 1.64 0.003 1.18-2.28
1.27 e 2.01 1.36 0.025 1.04-1.77
0.73 e 1.88
1.13 -1.67 1.36 0.006 1.09-1.70
0.82 e 1.18
1.33 e 2.36 1.94 <0.001 1.37-2.73
1.42 e 2.59 1.93 <0.001 1.36-2.75
Fig. 1. First line treatment-PFS1.
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Attrition rate in the whole population was of 9.67% between
first- and second-line treatment (PD1 observed in 575 patients,
missing data in 130 patients and second-line treatment started in
536). Particularly, attrition rate was 7.31%, 8.25% and 17.24% for CT,
ET alone and ET plus CDK4/6i, respectively. Moreover, probability to
receive CT after ET plus CDK4/6i (treated in first- and second-line)
was 52.80%. More in depth, the probability of receiving second- and
third-line CT after ET plus CDK4/6i was 53.84% and 53.26%,
respectively (Figure S5A, B).
Baseline characteristics at second-line that could influence the
choice of CT or ET after CDK4/6i were analyzed. None of the vari-
ables considered, including rapidly progressive disease (defined as
PFS 6 months at first-line) impacted on the choice of second-line
treatment after CDK4/6i (Table S4).
4. Discussion
The addition of CDK4/6i in combination to ET has dramatically
improved the clinical outcome of patients with luminal mBC,
leading to rapid approval of these agents and recommendation of
their use as the preferred first-line option by national and inter-
national guidelines [20,21].
The present study showed that first-line ET or CT alone were
associated, in a real-world cohort, with worse PFS compared to ET
plus CDK4/6i, with a 10 months difference in terms of mPFS1 for
patients treated with combination therapy (mPFS1 12 months for
CT, 14 months for ET and 22 months for ET plus CDK4/6i), consis-
tently with what was observed in all main phase III studies
[1,2,5,22].
Moreover, the present study showed a prolonged PFS2 in pa-
tients who received a CDK4/6i-based second-line as compared to
ET or CT alone (12 months for ET plus CDK4/6i, 7 months for ET
alone and 6 months for CT), consistently with PALOMA-3 trial
which demonstrated an improvement in median PFS with the
addition of Palbociclib to Fulvestrant of 9.5 months vs 4.6 months
(HR 0.46, 95% CI 0.36e0.59, p < 0.0001)23.
Furthermore, MONALEESA-3 trials demonstrated a statistically
significant benefit in OS with the combination of Ribociclib and ET.
Consistently, in the phase III MONARCH-2 trial, Abemaciclib
improved OS when combined with Fulvestrant in second-line (HR1080.75; 95% CI: 0.606e0.945; p ¼ 0.0137) [6,24e29]. Although the
present study showed a trend towards better prognosis in terms of
OS in patients treatedwith first-line CDK4/6i, themedian follow-up
was not adequate to generate conclusive results.
Notably, the study showed a greater improvement of CDK4/6i in
first-line rather than in second-line second (median PFS1 and PFS2
respectively 22 vs 12months) (Fig. 2). Moreover, the rate of patients
that developed visceral metastases after CDK4/6i was similar in
both second-line CT and ET cohorts. Conversely, the largest pro-
portion of patients who switched from non-visceral to visceral
involvement were those receiving ET followed by ET or CT
(P < 0.001) (Table S1).
Luminal mBC is a clinically and molecularly heterogeneous
disease, and the specific mechanisms though which it develops
resistance to ET and CDK4/6i are still not fully elucidated, hindering
the definition of biology-driven sequence strategies [12,14,16,30].
In the analyzed cohort, 60% of patients received CT and 40%
received ET after a first-line CDK4/6i-based strategy. About CT,
24 pts received capecitabine, 2 nab-paclitaxel, 2 vinorelbine and 1
paclitaxel. Interestingly, after CDK4/6i failure, a worse prognosis
was observed in patients who received CT over ET (HR 6.95,
p ¼ 0.01). Because of the potential bias that could have favored CT
assignment in patients with an impending visceral crisis and
therefore with an inherently worse prognosis, a logistic regression
model was developed to explore potential factors that could have
influenced clinical decision-making in second-line after CDK4/6i.
None of the analyzed factors seemed to influence the choice of
second-line CT or ET. Consistently, a recent study showed that ET
after a combination of ET and Palbociclib is still effective, leading to
a long median PFS2 after disease progression to first-line treatment
[31].
Results from a logistic regression analysis conducted on 525
patients who had previously received CDK4/6i suggested that pa-
tients treated with CT after CDK4/6i were more likely to have a
rapidly progressive disease compared to ET, everolimus or subse-
quent CDK4/6i (OR 0.46, 0.59, and 0.48)[32]. These observations
might support the choice of ET after disease progression on a CDK4/
6i in clinical practice.
The choice of second-line agents depends on previous lines of
treatment and, to date, current options in progressive disease after
CDK4/6i are represented by mTOR inhibitors (e.g everolimus plus
exemestane), ET alone, CDK4/6i, PI3K inhibitors or CT.
Table 3
Univariate and Multivariate analysis-OS




Variables HR P 95 % CI HR P 95 % CI HR P 95 % CI
Age (years)
< 45 1.00
45-65 0.97 0.812 0.73 e 1.28
> 65 1.26 0.111 0.95 e 1.66
BMI (kg/m2)
< 25 1.00
 25 0.90 0.292 0.73 e 1.10
ET naive
Yes 1.00
No 1.18 0.097 0.97 e 1.43
CT naive
Yes 1.00
No 1.03 0.746 0.85-1.25
De novo metastatic disease
No 1.00
Yes 0.93 0.494 0.75 e1.15
ER
10 % 1.00
>10 % 0.70 0.171 0.43 e 1.16
Ki-67 on primary tumor:
<14 % 1.00
14 % 1.80 <0.001 1.42 e 2.28 1.91 <0.001 1.47-2.49 2.00 <0.001 1.49-2.68
Metastatic sites score
No 1.00
Yes 1.10 0.369 0.89 e 1.37
Sites
Bone only 1.00
No visceral 1.25 0.107 0.95 e 1.62 1.30 0.119 0.93-1.82 1.23 0.263 0.86-1.76
Visceral 1.61 <0.001 1.30e 2.01 1.20 0.262 0.87-1.66 0.99 0.960 0.70-1.41
Sites score
<3 sites and 5 lesions 1.00
3 sites and 5 lesions/ < 3 sites and > 5 lesions 1.16 0.224 0.91 e 1.48 1.20 0.206 0.90-1.59 1.28 0.112 0.94-1.74
 3 sites and >5 lesions 1.97 <0.001 1.51 e 2.56 1.60 0.009 1.13-2.28 1.83 0.002 1.24-2.68
ECOG PS
 1 1.00
> 1 2.39 <0.001 1.89 e 3.02 2.07 <0.001 1.59-2.70 1.71 0.001 1.25-2.33
First-line therapy:
ET plus CDK 4/6 inhibitors 1.00
ET 1.39 0.149 0.89 e 2.18 1.40 0.173 0.86-2.29
CT 1.61 0.042 1.02 e 2.54 1.24 0.404 0.75-2.03
Treatment strategies
ET þCDK / ET 1.00
ETþ CDK /CT 6.95 0.011 1.56-30.83 5.05 0.035 1.12-22.72
ET / ET or CT 2.63 0.176 0.65-10.64 2.35 0.235 0.57-9.61
ET/ ET þ CDK 1.64 0.508 0.38-7.10 1.70 0.483 0.39-7.46
CT / CT or ET 2.93 0.133 0.72-11.87 2.05 0.318 0.50-8.39
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secondary endocrine resistance in luminal mBC and there is a
strong biological rationale supporting PI3K/AKT/mTOR axis as a
therapeutic target [33]. The phase III SOLAR 1 trial showed the ef-
ficacy and safety of the PI3K inhibitor Alpelisib plus Fulvestrant in
patients previously treated with ET (median PFS was 11 months in
the Alpelisib armvs 5.7months in the placebo arm; HR:0.65). These
results highlighted the potential need for an upfront evaluation of
the PIK3CA mutational status and support the use of Alpelisib in
mutated mBC with secondary resistance to ET [34]. However, this
type of treatment is not yet available in all countries, except in
clinical trials or specific programs.
Noteworthy, the efficacy of combinations of ETwithmTOR, PI3K,
and CDK4/6 inhibitors, the biological interplay between these
pathways and the sensitization of cancer mutant cells led to the
design of clinical studies investigating triplet combinations
[2e5,22,23,35e38].
Moreover, ESR1 mutations represent an established mechanism
of acquired resistance to AI and, therefore, a combination of the109same CDK4/6i with a more effective ET would overcome this
resistance [39]. A recent study conducted on 16 mBC patients
treated with Palbociclib and letrozole demonstrated that ESR1
mutations were significantly associated with worse PFS (3.3 vs 9.0
months; P ¼ 0.038)39.
Consistently, the preliminary results of the PADA-1 study, sug-
gested that the combination of Palbociclib with AIs could poten-
tially overcome the initial impact of ESR1 mutations, leading to the
clearance of mutated clones which eventually reoccurred at pro-
gression [40]. Of note, alternative resistance mechanisms could
affect the ESR1 gene, such as epigenetic alterations, which can lead
to early resistance and consequently to a dramatically shorter PFS1
under CDK4/6i [16].
Interestingly, the present study investigated attrition rate, a
promisingmetric in evaluating the opportunity to receive a second-
line treatment. Nuzzolese and Montemurro provided data on
attrition rates in CDK4/6i trials. In the first-line setting, attrition
rate ranged from 12% to 27% for ET and from 15% to 33% for CDK4/6i
(PALOMA-2, PALOMA-3, MONARCH-2, MONARCH-3, MONALEESA-
Fig. 2. AFirst-line treatment-OS. B. Treatment strategies-OS
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attrition rate was 7% for CT, 8% for ET and 17% for ET plus CDK4/6i
after first-line therapy. Moreover, the probability to receive CT after
CDK4/6i was 53%, regardless of the line of treatment, and approx-
imately 54% and 53% after first- and second-line therapy,
respectively.
This study, supports the hypothesis that second-line ET, com-
bined with other targeted molecules, might potentially represent a
feasible option after CDK4/6i failure, allowing to further postpone
CT to later lines.
Noteworthy, this analysis contributes to the generation of real
world data, which relevance has often been highlighted as an
essential integration of randomized trials. Indeed, the use of data
from the real-world scenario is garnering increased attention to
provide information about clinical-relevant questions that cannot110be answered using data from clinical trials [42].
Notwithstanding the intriguing insights, the present study has
some limitations, such as the retrospective design and the small
sample size. In particular, due to the paucity of patients receiving a
CDK 4/6 Inhibitor (141 patients in the first line setting and 61 pa-
tients in the 2nd line setting) results need to interpreted with
caution. Moreover, clinical decision-making is strongly influenced
by patients’ and diseases’ characteristics, including age, PS, prior
toxicities, potential adherence to treatment, previous treatment
route of administration, and time to progression, with all of these
characteristics being potentially sources of selection bias.
5. Conclusions
To date, first-line CDK4/6i-based therapies represent the gold
D. Basile, L. Gerratana, C. Corvaja et al. The Breast 57 (2021) 104e112standard in luminal mBC. The present study confirmed the signif-
icant impact of this strategy on a homogeneous real-world cohort.
Moreover, the study suggested a preeminent role for ET after first-
line CDK4/6i, supporting the concept of an ET switch to overcome
potential resistance mechanisms and restore clinical response. Due
to the retrospective nature of these results, further prospective
studies will be needed to confirm these observations and to build
the optimal treatment algorithms for luminal mBC.6. Clinical practice points
 First-line (1st L) CDK4/6i-based therapies represent the stan-
dard treatment in luminal mBC. However, prospective head-to-
head comparisons are still lacking for many 1st line options, and
it is still crucial to define the best treatment strategy for both 1st
and 2nd L.
 The present study confirmed the significant impact of 1st L
CDK4/6i-based therapies on a homogeneous real-world cohort.
Moreover, the study suggested a preeminent role for ET after
first-line CDK4/6i, supporting the concept of an ET switch to
overcome potential resistance mechanisms and restore clinical
response.
 The second-line ET, combined with other targeted molecules,
might potentially represent a feasible option after CDK4/6i
failure, allowing to further postpone CT to later lines.Credit author statement
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